The dvm360® oncology page is a comprehensive resource for clinical news and insights on the latest in veterinary oncology. This page consists of videos, interviews, articles, podcasts, and research on the advancements and developments of therapies for oncology, and more.
November 12th 2024
Canalevia-CA1 is currently the only treatment on the market for treating CID in canine patients.
September 24th 2024
Feline vaccine-associated sarcoma: myth or reality? (Proceedings)
August 1st 2010Vaccination has generally been considered to be a benign procedure in veterinary medicine. Unfortunately, soft tissue sarcoma development subsequent to vaccination (vaccine-associated sarcoma; VAS) in cats has dramatically changed this view within our profession over the last twenty years.
Of Mice & Men (and dogs!): Vaccines for cancer? (Proceedings)
August 1st 2010Canine malignant melanoma (CMM) of the oral cavity, nail bed, foot pad and mucocutaneous junction is a spontaneously occurring, highly aggressive and frequently metastatic neoplasm. CMM is a relatively common diagnosis representing ~ 4% of all canine tumors and it is the most common oral tumor in the dog.
Feline vaccinal sarcomas (Proceedings)
August 1st 2010The recognition of the development of potentially malignant tumors arising from injection sites became one of the most significant events in veterinary medicine in the 1980's and beyond. So significant, in fact, that it caused an entire profession to re-evaluate the way preventative medicine should be considered from a medical and an economic perspective.
New canine cancer research program dubbed an 'unprecedented' collaboration
June 6th 2010Phoenix, Ariz. -- The Translational Genomics Research Institute (TGEN) and the Van Andel Research Institute (VAI) have created a new Canine Hereditary Cancer Consortium, which aims to study naturally occurring cancers in dogs to better understand how the disease develops in both animals and humans.
Canine mast cell tumors: How do TK inhibitors fit? (Proceedings)
April 1st 2010One of the most common questions an oncologist hears from a pet owner is, "Why did my dog get cancer?" While it is often impossible to provide a specific answer for a specific patient, our understanding of why cancer develops has grown exponentially in the past decade. As are most things in the living organism, the causes are extremely complex, multifactorial, and still not completely understood.
Osteosarcoma and hemangiosarcoma: The ugly sarcomas (Proceedings)
April 1st 2010Osteosarcoma (OSA) and hemangiosarcoma (HSA) are highly malignant tumors that have both a locally invasive and highly metastatic biologic behavior. Multimodality therapy must be employed to provide patients with these cancers the best chance for improved quality and quantity of life.
Canine lymphoma: The naive patient (Proceedings)
April 1st 2010Canine lymphoma (LSA) makes up approximately 18% of all malignancies in the dog, and 80% of all hematopoietic tumors in dogs are LSA. Middle-aged dogs are most commonly affected; but out of cancers affecting young dogs (as young as 6 months), LSA is common.
Cancer is the easy part! Techniques to help with difficult clients (Proceedings)
April 1st 2010Speaking with pet owners is something veterinarians do constantly; as such, it is the most common "procedure" performed in veterinary medicine. Yet very few veterinarians receive any guidance in this critical area during veterinary school or after.
Chemotherapy safety: Why, when, and how (Proceedings)
April 1st 2010Chemotherapy safety can be broken down into two big categories: safety for the patient, and safety for the individuals handling the drugs. Understanding how chemotherapy works provides a background for knowing potential dangers of treatments as well as how to safely use these beneficial drugs.
Colorado State teams with Japan to research cancer therapy
March 23rd 2010Fort Collins, Colo. -- Colorado State University?s College of Veterinary Medicine and Biomedical Sciences will team with Japan?s Gifu University School of Medicine and its National Institute of Radiological Sciences (NIRS) to research a promising new treatment for cancer: carbon ion therapy.
CSU taps companies to collaborate on liposome-targeting technology for cancer therapeutics
February 8th 2010Fort Collins, Colo. ?- Colorado State University is looking to build new cancer therapeutics from its liposome-targeting technology. The university and NeoTREX (a division of CSU Ventures) inked an exclusive option agreement with Joveis, Inc. of Napa, Calif. for the development of these therapeutics.